Summary
A proposal for the nomination of the father of monoamine oxidase inhibitors is presented. A brief history of the human clinical pharmacology of selegiline is considered including the results of two major prospective ongoing clinical trials and recent evidence on the effects of sustained selegiline therapy on postural blood pressures in parkinsonians is discussed.
Keywords
- Postural Hypotension
- Monoamine Oxidase Inhibitor
- Mortality Figure
- Parkinson Study Group
- Postural Dizziness
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Beringer K (1928) Über ein neues, auf das extrapyramidal-motorische System wirkendes Alkaloid (Banisterin). Nervenarzt 1: 265–275
Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after 1-dopa treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm 36: 303–326
Birkmayer W, Knoll J, Riederer P, Youdim MBH, Harts V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–127
Blaschko H, Richter D, Schlossmann H (1937) The inactivation of adrenaline. J Physiol (Lond) 90: 1–15
Blaschko H, Richter D, Schlossmann H (1937) The oxidation of adrenaline and other amines. Biochem J 31: 2187–2196
Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 57: 33–38
Halpern L (1930) Ueber die Harminwirkung im Selbstversuch. Dtsch Med Wochenschr 56: 1252–1254
Hare MLC (1928) Tyramine oxidase. 1. A new enzyme system in the liver. Biochem J 22: 968–979
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469
Knoll J (1978) The possible mechanisms of action of (—)-deprenyl in Parkinson’s disease. J Neural Transm 43: 177–198
Knoll J, Ecsery Z, Kelemen K, Nievel JG, Knoll B (1965) Phenylpropylmethyl-propinylamine (E-250): a new spectrum psychic energizer. Arch Int Pharmacodyn 155: 154–164
Lees AJ, Shaw KM, Kohout L, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet ii: 791–795
Lewin L (1928) Untersuchungen uber Banisterin caapi Spr. Arch Exp Pathol Pharmakol 129: 133–149
Lewin L, Schuster P (1929) Ergebnisse von Banisterinversuchen an Kranken. Dtsch Med Wochenschr 55: 149
Mann J, Gershon S (1980) L-deprenyl, a selective monoamine oxidase inhibitor in endogenous depression. Life Sci 26: 877–882
The Parkinson’s Disease Research Group of the UK (1993) Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three year interim report. BMJ 307: 469–472
The Parkinson’s Disease Research Group of the UK (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 311: 1602–1607
The Parkinson’s Disease Research Group of the UK (1996) BMJ 312: 704–705 (letter)
The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371
The Parkinson Study Group (1996) Impact of Deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29–36
The Parkinson Study Group (1996) Impact of Deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects requiring levodopa. Ann Neurol 39: 37–45
Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542–544
Spruce R (1908) Notes of a Botanist on the Amazon and Ande, vol 11. Macmillan, London
Udenfriend S, Witkop B, Redfield BG, Wiessbach H (1958) Studies with reversible inhibitors of monoamine oxidase: harmaline and related compounds. Biochem Pharmacol 1: 160–165
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Wien
About this paper
Cite this paper
Stern, G. (1998). Neuroprotection by selegiline and other MAO inhibitors. In: Finberg, J.P.M., Youdim, M.B.H., Riederer, P., Tipton, K.F. (eds) MAO — The Mother of all Amine Oxidases. Journal of Neural Transmission. Supplement, vol 52. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6499-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6499-0_12
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83037-6
Online ISBN: 978-3-7091-6499-0
eBook Packages: Springer Book Archive